Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg/mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.

Abstract: Systems and methods for desalinating a liquid are provided. A desalination system may include a main container and may be configured to provide at least one of an electric field or a magnetic field through the main container to control a distribution of ions in a liquid in the main container.

Abstract: Embodiments of a power provision system of the present invention generally include a transformer, a drive assembly, a motor control center, rectifiers, circuit breakers, and a cooling system, all of which are enclosed in a cabinet that is divided into a plurality of compartments that house various components and that is adapted and configured to be skid mounted on a trailer. In one embodiment, high voltage power is supplied to the power provision system, wherein it is stepped down to lower voltages by the transformer and the lower voltage power is utilized to drive a fracking pump motor via the drive assembly, as well as auxiliary equipment, such as the cooling system, via the motor control center. Embodiments of a method of using the power provision system are also provided.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: The present invention relates to a dry powder pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) coarse lactose particles having a Dv50 of from 40 ?m to 80 ?m; and (iii) fine lactose particles having a Dv50 of from 5 ?m to 10 ?m, wherein: the fine lactose particles are present in an amount of from 0.1 wt % to 6.0 wt % relative to the total weight to the dry powder pharmaceutical composition. Also provided is a dry powder inhaler comprising the dry powder pharmaceutical composition and medical use of the dry powder pharmaceutical composition.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: Embodiments of a power provision system of the present invention generally include a transformer, a drive assembly, a motor control center, rectifiers, circuit breakers, and a cooling system, all of which are enclosed in a cabinet that is divided into a plurality of compartments that house various components and that is adapted and configured to be skid mounted on a trailer. In one embodiment, high voltage power is supplied to the power provision system, wherein it is stepped down to lower voltages by the transformer and the lower voltage power is utilized to drive a fracking pump motor via the drive assembly, as well as auxiliary equipment, such as the cooling system, via the motor control center. Embodiments of a method of using the power provision system are also provided.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: An improved mist generating apparatus is provided, the apparatus having a longitudinal axis (L), and first and second opposing nozzle surfaces (100,102) which define a nozzle between them. A first process fluid passage (28) has an inlet connectable to a supply of process fluid, and a process fluid outlet (110) on one or the first and second nozzle surfaces (100,102) such that the process fluid outlet (110) opens into the nozzle. The nozzle has a nozzle inlet (104) connectable to a supply of driving fluid, a nozzle outlet (108), and a throat portion (106) intermediate the nozzle inlet (104) and nozzle outlet (108). The nozzle throat (106) has a cross sectional area which is less than that of both the nozzle inlet (104) and the nozzle outlet (108). The nozzle extends radially away from the longitudinal axis (L) such that the nozzle defines a rotational angle about the longitudinal axis (L).

Abstract: A printing method includes programming a 3D printer to print a three-dimensional product, the three-dimensional product being one of a coin, a round, or a bar; selecting a precious metal from one of gold, silver, and copper; providing the 3D printer with the precious metal; directing the 3D printer to create the three-dimensional product with the precious metal; and applying a layer of graphene to a surface of the three-dimensional product; the layer of graphene provides protection to the three-dimensional product.

Abstract: Interactive system provides training and assessments relating to joint stabilization capabilities and reaction-based performance for diverse populations. This system may enhance the subject's ability to generate and deliver power as a direct byproduct of properly timed decelerations originating with the effectors and supported by the verticality of the spine. Said decelerations also provide functional means for improving joint stabilization capabilities via improved co-contraction of the shoulder(s) joints and other anatomical locations on the subject. The resulting data may serve as the basis for predictive analytics relating to joint stabilization and the associated risk of orthopedic injuries. This system may also train/improve the dampening of internal forces resulting from aggressive weight bearing movements, and more effectively dissipate the force of received physical impacts.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: Interactive system provides training and assessments relating to joint stabilization capabilities and reaction-based performance for diverse populations. This system may enhance the subject's ability to generate and deliver power as a direct byproduct of properly timed decelerations originating with the effectors and supported by the verticality of the spine. Said decelerations also provide functional means for improving joint stabilization capabilities via improved co-contraction of the shoulder(s) joints and other anatomical locations on the subject. The resulting data may serve as the basis for predictive analytics relating to joint stabilization and the associated risk of orthopedic injuries. This system may also train/improve the dampening of internal forces resulting from aggressive weight bearing movements, and more effectively dissipate the force of received physical impacts.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: Mixed reality collaboration applications and a mixed reality collaboration platform providing mixed reality collaboration are described. The platform can include a data resource with supported device information, registered user information, and session data stored on the data resource. Two or more devices (e.g., a first user device and a second user device) with different operating systems can register with the platform. The platform can store registration information, such as user device information and user information, received from the two or more devices in the data resource as part of the registered user information. The platform can receive, from the second user device, session data in a format compatible with the second user device operating system. The platform can then access the supported device information and communicate the session data to the first user device according to the API calls for the first user device.

Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

Abstract: In the field of experimental psychology, a “dual-task paradigm” is defined as a task that requires the subject to perform two tasks simultaneously, so that this effort can be compared to his/her performance under single-task conditions. Dual Task paradigms are frequently employed in research and healthcare to assess the cognitive and motor performance/status of an individual. Dual Task activities are integral to sport and other dynamic environments as the athlete's focus is often divided between cognitive and neuromuscular/musculoskeletal (“motor”) tasks. Known DT paradigms fail to replicate the challenges of actual sports; nor do they generate certain fundamental analytics/metrics regarding sports performance under realistic conditions. Simulation creates a novel DT paradigm to detect and manage conditions that may predispose active subjects to increased risk of overtraining, as well movement asymmetries that may expose one to increased risks of brain or orthopedic injuries.

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: A panel structure having a low-density core that can withstanding loads normal to a first primary surface, and a first facing of high-density sheet material that can extend along the first primary surface. The high-density sheet material can be laminated on the core such that the laminated core and facing cooperatively resist bending loads and loads along the primary surface. The first facing can extend from the first primary surface on a side of the core along a secondary surface, which can be non-parallel to the first primary surface. The first facing can bend along a score line between the first primary surface and the secondary surface.